Log in Free sign up

Catalyst Pharmaceuticals (CPRX) News and press releases

News

From Benzinga Pro

Catalyst Pharmaceuticals Q1 EPS $0.18 Beats $0.14 Estimate, Sales $43.10M Beat $42.75M Estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.14 by 28.57 percent. This is a 157.14 percent increase over earnings of $0.07 per

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Earnings Scheduled For May 10, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.

6 Best-Performing Robinhood Stocks Of 2022

Long Ideas, Small Cap, Top Stories, Trading Ideas

The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year, dropping 43.3%.

This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin

Cryptocurrency, Markets, Movers, Trading Ideas

Alpha Metallurgical Resources Inc (NYSE: AMR) is known as a leading American coal supplier, and over the past year, delivered shocking returns for bullish traders and investors.

Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings

Biotech, Earnings, News, Guidance, Health Care, Small Cap, General

Catalyst Pharmaceuticals's Return On Capital Employed Insights

According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million.

Recap: Catalyst Pharmaceuticals Q4 Earnings

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Catalyst Pharmaceuticals Q4 EPS $0.09 Misses $0.12 Estimate, Sales $38.31M Beat $38.19M Estimate

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.12 by 25 percent. This is a 18.18 percent decrease over earnings of $0.11 per share

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Earnings Scheduled For March 16, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million.

Earnings Preview For Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that Catalyst Pharmaceuticals will report an earnings per share (EPS) of $0.12.

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

Catalyst Pharmaceuticals aAnd KYE Pharmaceuticals Announce Canadian Federal Court Ruling Setting Aside Approval Of Ruzurgi

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for

Catalyst Pharma Reports US Patent & Trademark Office Notified Co. Added Patent Covering FIRDAPSE Tablets 10 mg Will Issue On Mar. 8, 2022, 2 Added Patents Will Issue On Mar. 15, 2022

Biotech, News, FDA, Legal, General

Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio Provides

Press releases

From Benzinga Pro

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

Earnings, Press Releases

Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY Three New Patents Issued; Now Five Orange-Book Listed Patents for FIRDAPSE® Significant Cash Position of $198 Million and No Funded Debt

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

News, Press Releases

CORAL GABLES, Fla., April 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Earnings, Press Releases

Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE Long-Term

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

Health Care, Press Releases

CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

Biotech, Health Care, Press Releases, General

CORAL GABLES, Fla., March 08, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

Biotech, News, Press Releases, General

CORAL GABLES, Fla., March 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Health Care, Press Releases

Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022 Reinforces and Diversifies FIRDAPSE Long-Term Patent Portfolio Patent Portfolio

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

Biotech, Health Care, Markets, Press Releases, General

Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders Together, Will Ring the Nasdaq Opening Bell to Kick-Off Rare Disease

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

Health Care, Press Releases, General

CORAL GABLES, Fla., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on developing and commercializing